IL6 and neoplasm: Our data support previous work showing that tumor IL-6 impacts myelopoiesis and MDSC [43], but importantly it also positions tumor-derived IL-6 as a negative regulator of the total CD4+ Th cell population, an effect that is particularly pronounced locally in the tumor (Figure 10).